Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

Graydon Miles was driving down Highway 7 in Ontario last year when he saw an upside down Maple Leaf flying from a pickup ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.

1. Publish the author or authors' name (s) and the title as written on the original column, and give credit to the Texas Politics Project at the University of Texas at Austin (and, if possible, a link ...

The Louisiana Department of Health "will no longer promote mass vaccination" according to a Thursday memo written by the ...

When COVID-19 swept across the globe, isolation, social distancing and wearing masks became the norm. Now, a new risk for anyone who has ever tested positive.

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...